<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04741633</url>
  </required_header>
  <id_info>
    <org_study_id>CID-001</org_study_id>
    <nct_id>NCT04741633</nct_id>
  </id_info>
  <brief_title>Multi Dimensional Precise Exploration of Immunoconsolidation Therapy for Locally Advanced NSCLC After Chemo-radiotherapy</brief_title>
  <acronym>NSCLC</acronym>
  <official_title>Multi Dimensional Precise Exploration of Immunoconsolidation Therapy for Locally Advanced Non-small Cell Lung Cancer After Chemo-radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to carry out a prospective observational study in patients with&#xD;
      locally advanced NSCLC receiving radical concurrent chemoradiotherapy and follow-up immune&#xD;
      consolidation therapy. By detecting ctDNA and TILs of the patients, we explored the value of&#xD;
      blood dynamic monitoring of ctDNA in patients with prognosis stratification and treatment&#xD;
      effect, and explored the patients before and after concurrent chemoradiotherapy and immune&#xD;
      consolidation therapy The characteristics of DNA, RNA, T cells and other biomarkers were&#xD;
      correlated with the efficacy and prognosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between ctDNA dynamic detection and 1-year PFS rate after chemoradiotherapy</measure>
    <time_frame>Six months after consolidation treatment</time_frame>
    <description>The ctDNA dynamic detection will contain NGS test including mutations(both somatic and germline), copy number variations, gene fusions along with genetic interpretation for each and every mutation identified in each test(both blood and tissue) during the whole therapeutic process</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>Six months after consolidation treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>Six months after consolidation treatment</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">25</enrollment>
  <condition>NSCLC</condition>
  <condition>Chemoradiotherapy</condition>
  <condition>ctDNA</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with locally advanced NSCLC receiving radical concurrent chemoradiotherapy and&#xD;
        subsequent immunoconsolidation therapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Non small cell lung cancer patients confirmed by pathology;&#xD;
&#xD;
          2. They were 18-80 years old;&#xD;
&#xD;
          3. The tumor could not be resected or could not tolerate surgery;&#xD;
&#xD;
          4. Planed to receive chemoradiotherapy and subsequent immunoconsolidation therapy;&#xD;
&#xD;
          5. Clinical stage III (AJCC, 8th Edition, 2017);&#xD;
&#xD;
          6. After systematic detection of non-small cell lung cancer core indicators including&#xD;
             EGFR, ALK, ros1, KRAS, ntrk, TMB, etc;&#xD;
&#xD;
          7. Patient informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. After radiotherapy and chemotherapy, the disease progressed and immune maintenance&#xD;
             therapy could not be carried out&#xD;
&#xD;
          2. It can not cooperate with the completion of baseline mutation screening and subsequent&#xD;
             sample detection&#xD;
&#xD;
          3. Factors judged by other researchers not suitable for further study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xi Yang, Phd</last_name>
      <phone>+86 17321296901</phone>
      <email>ntgeroge@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 2, 2021</study_first_submitted>
  <study_first_submitted_qc>February 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zhengfei Zhu</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

